Last reviewed · How we verify
NCT01110928
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
trial testing somatropin in Foetal Growth Problem in 227 participants. Completed in 12 November 2018.
12 November 2018
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 227 |
| Start date | 26 November 2009 |
| Primary completion | 12 November 2018 |
| Estimated completion | 12 November 2018 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- somatropin (Somatropin) — full drug profile →
Conditions studied
- Foetal Growth Problem — all drugs for Foetal Growth Problem →
- Small for Gestational Age — all drugs for Small for Gestational Age →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
Eligibility, any sex, with Foetal Growth Problem or Small for Gestational Age. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is conducted in Japan. The aim of this observational study is to collect information about the safety and efficacy of Norditropin® in the long-term treatment of patients with a SGA (small for gestational age) short stature where the growth plate in the long bones (epiphyseal disc) is not closed. An extension to the GHLIQUID-1517 trial (NCT00184717).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The long-term safety and effectiveness of growth hormone treatment in Japanese children with short stature born small for gestational age.
Horikawa R, Tanaka T, Nishinaga H, Nishiba Y, et al · · 2020 · cited 17× · PMID 33088015 · DOI 10.1297/cpe.29.159
Verify or expand the search:
- PubMed search for NCT01110928
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of somatropin
Trials testing the same drug.
- NCT02726542 — Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents · EARLY_PHASE1 · completed
- NCT02382939 — A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Prev · Phase 3 · completed
- NCT02229851 — Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropi · Phase 3 · completed
- NCT02092077 — A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children · Phase 2 · terminated
- NCT01973244 — A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth · Phase 1 · completed
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01110928 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 11 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01110928.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing